Optimizing Chloroquine to Make a Better Drug to Fight Malaria

Optimization of chloroquine to make better medicines against malaria Abstract: Malaria has plagued human beings for centuries. It is possible to discover chloroquine in drug experiments by humans. This is probably the most successful way to treat parasitic infections. However, the new malaria strain, Plasmodium falciparum, Plasmodium falciparum has been shown to be resistant to chloroquine and other treatments for this deadly disease. Men should give up this ancient medicine. Before trying to optimize it to fight against malaria again.

The complex amine-phenolic Ga (III) compound MR045 is selectively toxic to the chloroquine parasite, a common drug against malaria. Both the Ga (III) complex and chloroquine act by inhibiting the crystallization of hemozoin (processed products formed by parasite-digested blood). Gallium-67 salts such as gallium citrate and gallium nitrate are used as radiopharmaceuticals in nuclear medicine imaging known as gallium scans. The radioactive isotope 67 Ga is used and the compound or salt of gallium is not important. The body treats Ga 3+ in a number of ways as if it is Fe 3+, and the ions bind (and enrich) inflammation (eg infection) and regions of rapid cell division. This allows imaging of these sites by nuclear scanning technique

Quinine and its dextro isomer, quinidine, was the last drug to treat malaria, particularly serious diseases. Chloroquine is the quinine 4-aminoquinoline derivative that was first synthesized in 1934 and became the most widely used antimalarial drug since then. Historically, tolerance greatly reduced its effectiveness, but it was a drug selected for treatment of malaria and chemoprevention without non-severe or complications. Amodiaquin is a relatively wide range